Turtle Creek Wealth Advisors LLC Purchases 8,559 Shares of AbbVie Inc. $ABBV

Turtle Creek Wealth Advisors LLC lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 70.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 20,751 shares of the company’s stock after buying an additional 8,559 shares during the quarter. Turtle Creek Wealth Advisors LLC’s holdings in AbbVie were worth $4,741,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Brighton Jones LLC grew its position in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after acquiring an additional 3,401 shares during the period. Revolve Wealth Partners LLC grew its position in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after acquiring an additional 3,064 shares during the period. Schnieders Capital Management LLC. boosted its holdings in AbbVie by 5.0% in the 2nd quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after buying an additional 789 shares during the period. Ieq Capital LLC boosted its holdings in AbbVie by 4.6% in the 2nd quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock worth $22,281,000 after buying an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC boosted its holdings in AbbVie by 117.3% in the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock worth $210,685,000 after buying an additional 612,702 shares during the period. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Canaccord Genuity Group assumed coverage on shares of AbbVie in a report on Monday. They issued a “buy” rating and a $262.00 target price for the company. Citigroup decreased their price target on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 27th. Barclays started coverage on shares of AbbVie in a research note on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target on the stock. Morgan Stanley boosted their price target on shares of AbbVie from $269.00 to $270.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Finally, UBS Group decreased their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $253.19.

Insider Buying and Selling at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares of the company’s stock, valued at $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.06% of the company’s stock.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $1.4 billion, 185‑acre pharmaceutical manufacturing campus in Durham, NC — its largest-ever single-site capital investment — which management says will add advanced, AI-enabled production capacity for immunology, neuroscience and oncology drugs and create hundreds of jobs; investors view this as a long-term capacity and supply-chain strengthening move. Read More.
• Positive Sentiment: Analyst sentiment turned more constructive: Canaccord initiated coverage with a Strong Buy / $262 price target, which supports upside expectations and likely helped buying interest after the campus announcement. Read More.
• Neutral Sentiment: AbbVie struck an exclusive licensing deal with Haisco to develop pain medicines (AbbVie will own development/manufacturing/commercial rights) — a potentially positive medium-term pipeline expansion, but impact depends on development milestones and commercialization timing. Read More.
• Neutral Sentiment: Investors are also watching upcoming Q1 earnings (Apr. 29) and consensus estimates; previews and models are circulating (Zacks and others) and could re-rate the name depending on results vs. guidance. Read More.
• Negative Sentiment: The FDA issued a Complete Response Letter (CRL) for AbbVie’s trenibotulinumtoxinE (TrenibotE) BLA, citing manufacturing-process concerns; the agency did not request new clinical studies but requires AbbVie to resolve manufacturing questions before approval — this delays a potential new product launch and creates near-term revenue uncertainty for the neurotoxin program. Read More.
• Negative Sentiment: Regulatory focus on manufacturing (FDA requests for additional information / manufacturing concerns highlighted in multiple reports) increases scrutiny on AbbVie’s production controls and could raise near-term remediation costs or timelines. AbbVie says it is well-positioned to address the FDA’s comments, but the issue tempers enthusiasm until resolved. Read More.

AbbVie Stock Up 0.2%

Shares of ABBV opened at $200.97 on Friday. The company has a market cap of $355.34 billion, a price-to-earnings ratio of 85.15, a price-to-earnings-growth ratio of 0.72 and a beta of 0.38. AbbVie Inc. has a twelve month low of $176.11 and a twelve month high of $244.81. The company has a 50 day moving average of $217.33 and a two-hundred day moving average of $222.62.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. AbbVie’s revenue was up 10.0% compared to the same quarter last year. During the same period last year, the firm earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 14.22 EPS for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.